Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab
Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab
复制标题
DOI：
10.1007/s00701-019-03825-4
复制
发表时间：
2019-02
影响因子：
2.4
通讯作者：
Atsushi Ogata;K. Oho;Noriaki Matsumoto;J. Masuoka;Kohei Inoue;Motofumi Koguchi;Fumitaka Yoshioka;T. Abe
中科院分区：
文献类型：
--
作者：
Atsushi Ogata;K. Oho;Noriaki Matsumoto;J. Masuoka;Kohei Inoue;Motofumi Koguchi;Fumitaka Yoshioka;T. Abe
前蛋白转化酶枯草杆菌蛋白酶/kexin 9型（PCSK 9）抑制剂是一类新型单克隆抗体，可降低低密度脂蛋白胆固醇水平，改善心肌梗死和卒中的结局。然而，PCSK 9抑制剂对颈动脉斑块的影响仍不清楚。我们描述了3例接受PCSK 9抑制剂alirocumab治疗进行性颈动脉狭窄的患者，尽管接受了降脂他汀类药物治疗。所有三名患者在磁共振（MR）斑块成像上都有易损斑块。在alirocumab治疗开始后，没有患者发生卒中或不良事件，并且在MR斑块成像上观察到颈动脉斑块稳定。
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a novel class of monoclonal antibodies, reduce low-density lipoprotein cholesterol levels and improve outcomes of myocardial infarction and stroke. However, the effects of PCSK9 inhibitors on carotid plaques remain unclear. We describe three patients treated with PCSK9 inhibitor alirocumab for progressive carotid stenosis despite lipid-lowering statin therapy. All three patients had vulnerable plaques on magnetic resonance (MR) plaque imaging. After alirocumab treatment initiation, no patients suffered stroke or adverse events, and the stabilization of the carotid plaques was observed on MR plaque imaging.